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The androgen receptor (AR) is required for castra-
tion-resistant prostate cancer (CRPC) progression,
but the function and disease relevance of AR-bound
enhancers remain unclear. Here, we identify a group
of AR-regulated enhancer RNAs (e.g., PSA eRNA)
that are upregulated in CRPC cells, patient-derived
xenografts (PDXs), and patient tissues. PSA eRNA
binds to CYCLIN T1, activates P-TEFb, and promotes
cis and trans target gene transcription by increasing
serine-2 phosphorylation of RNA polymerase II (Pol
II-Ser2p). We define an HIV-1 TAR RNA-like (TAR-L)
motif in PSA eRNA that is required for CYCLIN T1
binding. Using TALEN-mediated gene editing we
further demonstrate that this motif is essential for
increased Pol II-Ser2p occupancy levels and CRPC
cell growth. We have uncovered a P-TEFb activation
mechanism and reveal altered eRNA expression that
is related to abnormal AR function and may poten-
tially be a therapeutic target in CRPC.INTRODUCTION
Androgen deprivation therapy has long been the mainstay
of treatment for advanced prostate cancer, but tumors inevitably
become castration resistant (Debes and Tindall, 2004). In-
creasing evidence suggests that persistent androgen receptor
(AR) signaling plays an essential role in development of hormone
therapy resistance. A number of AR-centered mechanisms haveThis is an open access article under the CC BY-Nbeen identified, includingAR gene amplification, mutations in the
AR ligand-binding domain, modulation of AR functions by up-
stream signaling pathways, and expression of AR splice variants
(Feldman and Feldman, 2001; van der Steen et al., 2013). The
discovery of castration-resistant prostate cancer (CRPC) depen-
dence on the AR signaling has led to the development of second-
generation endocrine therapeutics such as abiraterone and
enzalutamide (de Bono et al., 2011; Scher et al., 2012). Enzaluta-
mide acts to affect AR nuclear translocation and impairs AR
transcriptional activation (Tran et al., 2009). Abiraterone is a cy-
tochrome P450 17A1 (CYP17A1) inhibitor that blocks intratu-
moral androgen synthesis (Attard et al., 2008). Despite the
increased benefit of the new regimens in overall survival, most
patients develop resistance after initial responses (Scher et al.,
2010); thus, a cure for CRPC remains elusive.
Developmental or tissue-specific gene expression is estab-
lished primarily by transcription regulatory machineries at en-
hancers (Ong and Corces, 2011). Seminal works show that a
class of non-coding RNAs, so-called enhancer RNAs (eRNAs),
is widely transcribed from cell-lineage-specific enhancers (De
Santa et al., 2010; Kim et al., 2010; Ørom et al., 2010; Wang
et al., 2011). Further studies reveal that eRNAs are expressed
in a large spectrum of cell types (Hah et al., 2015; Lam et al.,
2013; Melo et al., 2013; Mousavi et al., 2013; Qian et al., 2014).
In mouse cortical neurons, the abundance of eRNA at neuronal
gene enhancers strongly correlates with the mRNA expression
of nearby genes (Kim et al., 2010). Mechanistic studies show
that, in a locus-specific manner, eRNAs act in cis to stabilize
enhancer-promoter looping, establish chromatin accessibility,
or facilitate release of the negative elongation factor (NELF)
complex (Hsieh et al., 2014; Li et al., 2013; Mousavi et al.,
2013; Schaukowitch et al., 2014). Estrogen-receptor (ER)- orCell Reports 15, 599–610, April 19, 2016 ª2016 The Authors 599
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
AR-regulated eRNAs also act in trans to regulate gene expres-
sion in hormone-responsive cells, but the effects appear to be
relatively infrequent in the cell types examined (Hsieh et al.,
2014; Li et al., 2013).
Amajor step in regulation of gene transcription is the assembly
of the preinitiation complex that brings RNA polymerase II (Pol II)
to gene promoters. Intriguingly, Pol II is often paused around 20–
60 nt downstream of the transcription start site (TSS). Pol II
release is achieved primarily by the activation of the positive
transcription elongation factor (P-TEFb), which promotes phos-
phorylation of at least three targets, including NELF, DRB-sensi-
tivity-inducing factor (DSIF), and serine 2 in heptad repeats in the
C-terminal domain (CTD) of the large subunit of Pol II (Pol II-Ser2)
(Peterlin and Price, 2006; Zhou et al., 2012). P-TEFb is a hetero-
dimer composed of cyclin-dependent kinase 9 (CDK9) and one
of the C-type cyclins, including T1, T2a, and T2b, of which
CYCLIN T1 is the most abundant partner (Peng et al., 1998).
Approximately 50% of the total P-TEFb is present in an inactive
form, due to the binding of the inhibitory ribonucleoprotein
complex composed of 7SK small nuclear RNA (snRNA) and
HEXIM1/2 (Nguyen et al., 2001; Yang et al., 2001). The trans-acti-
vating responsive (TAR) RNA at the 50 end of the HIV-1 transcript
and the 30 hairpin of 7SK share a similar secondary structure (Egl-
off et al., 2006). TAR RNA interacts with the HIV-1 transcription
activator Tat to form a protein complex that activates P-TEFb
by competing away the inhibitory subunit 7SK-HEXIM1/2 (Egloff
et al., 2006; Roy et al., 1990). BRD4 is another important
activator of P-TEFb (Jang et al., 2005; Yang et al., 2005). BRD4
activates P-TEFb by recruiting JMJD6, which mediates the de-
capping/demethylation of 7SK and the dismissal of the 7SK/
HEXIM1/2 inhibitory complex (Liu et al., 2013).
Significant progress has been made in elucidation of cellular
functions of eRNAs in various tissue types. However, current
knowledge about the mechanisms of action of eRNAs in gene
transcription regulation and their roles in human diseases such
as cancer is very limited. In the present study, we demonstrated
that a group of AR-regulated enhancer RNAs (AR-eRNAs), such
as PSA (or called KLK3) eRNA, are upregulated in CRPC cells in
culture and patient specimens. We further showed that PSA
eRNA binds to CYCLIN T1, activates P-TEFb, and increases
Pol II-Ser2 phosphorylation (PolII-Ser2p). We found that this ef-
fect is mainly mediated through a TAR-L motif.
RESULTS
AR-eRNAs Are Upregulated in Human CRPC Cells and
Patient Tissues
Given the pivotal role of AR function in CRPC progression, we
sought to assess genome-wide AR activity by profiling AR-
eRNA expression in CRPC cells. We used androgen-dependent
LNCaP and its castration-resistant derivative C4-2 (Dehm and
Tindall, 2006) as model systems. We performed strand-specific,
ribosome-minus RNA sequencing (RNA-seq) in these cell lines.
The hypersensitivity and large dynamic range of RNA-seq al-
lowed us to identify and quantify the expression of both eRNAs
and mRNAs. We performed, in parallel, AR chromatin immuno-
precipitation and deep sequencing (ChIP-seq) to define the
AR-binding sites in the genome. By assigning eRNAs to the near-600 Cell Reports 15, 599–610, April 19, 2016est genes, we found that a total of 6,193 AR-eRNAs were ex-
pressed at AR-bound enhancers in both LNCaP and C4-2 cells
(Figure 1A). A meta-analysis of published ChIP-seq data from
LNCaP cells (Wang et al., 2011) indicates that these are authentic
enhancers, as evident by the enrichment of AR coregulators
(FOXA1, MED12, and P300), Pol II, H2AZ, and enhancer histone
marks H3K4me1, H3K4me2, andH3K27ac (Figure 1A). Similar to
a bimodal pattern of H3K4me2 at AR-bound enhancers (He et al.,
2010), very low or no eRNA signals were detected in the center
of the AR-binding sites but increased bilaterally, reminiscent
of eRNA expression revealed by the global nuclear run-on
sequencing (GRO-seq) data (Wang et al., 2011) (Figure 1A). In
agreement with the previous report (Pekowska et al., 2011),
H3K4me3 was also detectable at these transcriptionally active
enhancers, but its level was much lower than that of the canon-
ical enhancer histone marks (Figure 1A). The averaged RNA-seq
signal intensities of 6,193 AR-eRNAswere globally higher in C4-2
cells compared to LNCaP cells when cultured under androgen
deprivation conditions (Figure 1B). Unsupervised clustering ana-
lyses revealed that, among these AR-eRNAs, 1,865 (30%) were
upregulated in C4-2 compared to LNCaP cells (Figures 1C and
1D), 923 (15%) were downregulated in C4-2, and 3,405 (55%)
exhibited no statistically significant differences between these
two cell lines. Upregulation of AR-eRNAs in C4-2 cells is exem-
plified by the well-studied AR target gene PSA (the third most
highly expressed eRNA identified in C4-2 cells; see Table S1)
and another AR target gene ARHGEF26 (the most highly ex-
pressed eRNA; see Table S1) (Figure 1E). We conclude that
expression of a large set of AR-eRNAs is aberrantly upregulated
in C4-2 CRPC cells in culture.
To further investigate AR-eRNA expression in CRPC cells, we
focused on the top five highly expressed cancer-relevant genes:
ARHGEF26, KLK15, HTR3A, TLE1, and SLC16A7 (Table S1).
RNA-seq data revealed that eRNA peaks at these loci were inter-
genic (Figures 1E and S1A). Upregulation of these genes at the
mRNA and protein levels in C4-2 CRPC cells and androgen regu-
lation of their expression in androgen-sensitive LNCaP cells
were confirmed by RT-qPCR and western blot (Figure 2A; Fig-
ure S1B). Substantial interactions between the promoters and
the putative enhancers at these loci were validated by chromo-
some conformation capture (3C) assays in C4-2 and androgen-
stimulated LNCaP cells (Figure 2B).
eRNA and mRNA expression at these loci were upregulated in
CRPC patient-derived xenografts (PDXs) and patient samples
compared to their hormone-naive counterparts (Figures 2C–2E
and S1C). PSA eRNAs were also upregulated in CRPC patient
samples (Figures 2D and 2E). Analysis of a previously reported
dataset (Grasso et al., 2012) indicated that the expression of
HTR3A and TLE1 was particularly upregulated in metastatic
CRPC patient samples compared to primary tumors (Fig-
ure S1D). We also analyzed mRNA expression of these five
genes in two additional CRPC datasets in the public domain
(Glinsky et al., 2005; Yu et al., 2004). We demonstrated that dif-
ferential expression of these genes stratified prostate cancer pa-
tients into two subgroups, in which higher expression of these
genes was associated with lower biochemical recurrence-free
survival, and the discriminating power was consistent in these
two independent cohorts of patients (Figure S1E). Thus, through
Figure 1. Upregulation of AR-eRNAs in CRPC Cells
(A) Aggregate plots showing the distribution of average tags (signal per million mapped reads) of AR ChIP-seq and RNA-seq around AR binding sites in LNCaP
and C4-2 cells. Other signature profiles were obtained from LNCaP cells reported previously (Wang et al., 2011).
(B) Genome-wide comparison of AR-eRNA levels between LNCaP (solid line) and C4-2 (dashed line) cells.
(C) Box-and-whisker plot showing AR-eRNA signals upregulated in C4-2 at 1,865 AR-bound enhancers. p < 2.2e16 (Wilcoxon test).
(D) Heatmap showing the unsupervised clustering of AR-eRNA signals upregulated in C4-2 cells at 1,865 AR-bound enhancers (right) and AR ChIP-seq signals
within ±1 kb windows centered on AR binding sites (left).
(E) Screen shots from the UCSC genome browser showing signal profiles of eRNA expression in LNCaP and C4-2 cells and ChIP-seq in LNCaP cells. The eRNA
and mRNA regions are highlighted in yellow. Left: PSA. Right: ARHGEF26.eRNA profiling analyses, we identified a subset of AR-regulated
geneswhose expression is associatedwith CRPCprogression in
patients.
PSA eRNA Regulates Pol II-Ser2p in the cis Locus
We found that the AR was required for AR-eRNA expression in
C4-2 cells (Figure S1F). However, upregulation of AR-eRNAs in
C4-2 cells was unlikely caused by increased expression of AR
protein, because little or no difference in AR protein level was de-
tected in C4-2 and LNCaP cells, regardless of androgen treat-ment (Figure S1G), which is consistent with the previous report
(Dehm and Tindall, 2006). No significant correlation was
observed between the expression of AR-eRNAs (or correspond-
ing mRNAs) and AR binding at the 1,865 enhancers where AR-
eRNAs were upregulated in C4-2 cells (Figure S1H). ChIP assays
demonstrated that active histone modifications such as
H3K4me1 and H3K27ac were upregulated, but the repressive
histone modification H3K9me2 was downregulated in the AR-
eRNA-expressing enhancers examined in C4-2 compared to
LNCaP cells (Figure S1I). Thus, it appears that the active histoneCell Reports 15, 599–610, April 19, 2016 601
Figure 2. Identification of Five New AR
Target Genes Whose Expression Is Upregu-
lated in CRPC Tissues
(A) eRNA expression and mRNA expression of five
new AR target genes (ARHGEF26, KLK15, HTR3A,
TLE1, and SLC16A7) were measured by RT-qPCR.
Data indicate means ± SD (n = 3). *p < 0.05.
(B) Evaluation of the enhancer-promoter interaction
at novel AR target gene loci by 3C assays. F, for-
ward primer; R, reverse primer; Mib, Mibolerone.
(C) eRNA expression and mRNA expression of five
new AR target genes were measured by RT-qPCR
in androgen-dependent (23.1) and castration-
resistant (23.1AI) PDXs grown in mice. Data indi-
cate means ± SD (n = 3).*p < 0.05; **p < 0.01.
(D and E) Heatmap of PSA eRNA and eRNA/mRNA
expression of five new AR target genes in human
primary prostate cancer (PCa) and CRPC tissues
obtained from Mayo Clinic (D) and Shanghai
Changhai Hospital (E) (PSA eRNA expression in
CRPC versus PCa, p = 0.000264 and p = 0.027184,
respectively).modifications, but not the AR protein level, are responsible for
the increased expression of AR-eRNAs in C4-2 CRPC cells.
Similar to the previous findings in cortical neurons (Kim et al.,
2010), our RNA-seq data revealed a global correlation between
eRNA and mRNA expression in both LNCaP (r = 0.59) and
C4-2 (r = 0.56) cells (Figure S2A). Therefore, we sought to deter-
mine the functional importance of AR-eRNAs in the regulation of
AR target gene mRNA expression in CRPC cells. Knockdown of602 Cell Reports 15, 599–610, April 19, 2016PSA eRNA by sequence-specific small
interfering RNAs (siRNAs) significantly
decreased PSA mRNA expression in
C4-2 cells (Figure S2B). To avoid the po-
tential off-target effect of siRNAs, highly
optimized generation-2.5 antisense oligo-
nucleotides (ASOs) (Burel et al., 2013),
which induceRNase-H-dependent degra-
dation of the complementary target RNA
without involving the cellular RNAi ma-
chinery, were used as an independent
approach to knock down PSA eRNA.
The levels of PSA eRNAs, unlike the other
AR-eRNAs examined, were effectively
reduced by two independent ASOs of
PSA eRNAs (Figure 3A; Figure S2C).
Similar to siRNAs, treatment of C4-2 cells
with ASOs also significantly reduced PSA
mRNA expression (Figure 3A). The consis-
tent results obtained from two indepen-
dent knockdown methods suggest a cis
function of PSA eRNA in regulating PSA
mRNA expression in CRPC cells.
Pol II-Ser2p is required for productive
transcription elongation and gene expres-
sion (Zhou et al., 2012). Therefore, we
examined whether PSA eRNA expression
affects Pol II-Ser2p at the PSA locus.Knockdown of PSA eRNA by siRNAs decreased the Pol II-
Ser2p level in the PSA promoter in both LNCaP and C4-2 cells
(Figure S2D). Similarly, knockdown of PSA eRNAs by ASOs
resulted in a decrease in Pol II-Ser2p at the PSA promoter in
C4-2 cells, which was accompanied by an increase in total
Pol II, although no overt change in unphosphorylated Pol II was
detected (Figures 3B and S2E). While Pol II promoter proximal
pause release and Pol II-Ser2p are achieved mainly through
Figure 3. PSA eRNA Regulates Pol II-Ser2p at Both cis and trans Targets
(A) Effectiveness of PSA eRNA knockdown mediated by sequence-specific ASOs and its effect on PSA mRNA expression. Data indicate means ± SD (n = 3).
**p < 0.01. Ctrl, control.
(B) ChIP-qPCR analysis of Pol II-Ser2p at the PSA gene locus in C4-2 cells. Immunoglobulin G (IgG) was used as a control. ChIP DNA was analyzed by real-time
PCR. Data indicate means ± SD (n = 3). *p < 0.05, compared to control 1.
(C) Heatmap of 674 gene loci showing Pol II-Ser2p signals were downregulated in C4-2 cells transfected with PSA eRNA siRNAs.
(D) Screen shots from the UCSC (University of California, Santa Cruz) Genome Browser showing ChIP-seq signal profiles of Pol II-Ser2p, total Pol II, and CYCLIN
T1 binding in C4-2 cells transfected with control or PSA eRNA siRNAs. Left: VEGFA. Right: SLC45A3.the action of P-TEFb composed of CYCLIN T and CDK9, we
found that PSA eRNA knockdown had little or no effect on
CYCLIN T1 binding in the PSA promoter (Figure S2F). Moreover,
AR ChIP-seq analyses showed that PSA eRNA knockdown in
C4-2 cells slightly decreased AR binding at the PSA promoter,
but the decrease was not statistically significant (Figure S2G).
This result was further confirmedbyARChIP-qPCR (Figure S2G).
Reduction in PSA eRNA also decreased Pol II-Ser2p occupancy
levels at genomic areas corresponding to the coding sequence
(CDS) and 30 UTR (Figure 3B). These data suggest that PSA
eRNA plays a critical cis role in regulating Pol II-Ser2p levels at
the PSA gene locus.
PSA eRNA Regulates Pol II-Ser2p at trans Target Loci
Most ER eRNAs examined are expressed at very low levels (5–15
copies per cell) in breast cancer cells, and the trans effects of ER
eRNAs are relatively infrequent (Li et al., 2013). Given that thetrans effects of PSA eRNA were observed in androgen-sensitive
LNCaP cells (Hsieh et al., 2014), wemeasured the copy numbers
of PSA eRNA in LNCaP and C4-2 cells. PSA eRNA levels were
low (52 ± 11 copies per nucleus) in LNCaP cells but were >15-
fold higher (831 ± 86 copies per nucleus) in C4-2 cells (Fig-
ure S2H). These results prompted us to determine the global
trans effect of PSA eRNA knockdown on Pol II-Ser2p levels.
We performed Pol II-Ser2p, as well as total and unphosphory-
lated Pol II ChIP-seq, in mock and PSA eRNA siRNA-treated
C4-2 cells. Given that P-TEFb (CYCLIN T1 and CDK9) is the
major factor responsible for Pol II-Ser2p, we also performed
CYCLIN T1 ChIP-seq. PSA eRNA knockdown significantly
decreased Pol II-Ser2p levels at the loci of a subset of genes
(674 targets, false discovery rate [FDR] < 0.001), which include
the cis target PSA and the known (FKBP5 and NKX3.1) (Hsieh
et al., 2014) and new trans targets, with functions in regulation
of cell cycle, growth, survival, migration, and invasion, such asCell Reports 15, 599–610, April 19, 2016 603
VEGFA, NCAPD3 (Liu et al., 2010), ADAMTS1 (Carver et al.,
2009), and IGF1R (Figures 3C, 3D, and S2I; Table S2). PSA
eRNA knockdown had little or no effect on occupancy of unphos-
phorylated Pol II and ARat the 674 targets (Figures S2J andS2K).
While Pol II-Ser2p was apparently reduced by PSA eRNA knock-
down at these loci, overall changes in total Pol II (including in-
crease in the promoter and decreased occupancy in the gene
body, as measured by traveling ratio) were relatively small (Fig-
ures S2K–S2M), making the explanation likely to be the changes
in both transcription and processing. Indeed, consistent with the
previous finding in Drosophila that decreased Pol II-Ser2p de-
creases mRNA levels by affecting mRNA 30 processing (Ni
et al., 2004), we found that the ratio of cleaved to uncleaved
RNA in the control knockdown cells was much greater than that
in PSA eRNA knockdown cells at three out of five loci examined
(Figure S2N). These data suggest that the effect of PSA eRNA
knockdown on gene expression can be attributed to a combina-
tion of reduced transcription and defective 30 processing.
Little or no change in CYCLIN T1 binding in the majority (498 of
674, approximately 74%) of these loci was detected consistently
among the replicates (Table S3). Notably, 586 out of 674 loci
(87%) had AR binding within 50 kb around the TSS (Table S2),
and among the top 25 hits were known AR-regulated genes
(e.g., NDRG1, FKBP5, SLC45A3, and TMPRSS2) (Figure 3C;
Table S2), suggesting the importance of PSA eRNA in regulating
AR signaling. ChIP-qPCR and RT-qPCR assays further con-
firmed that knockdown of PSA eRNA by two independent
ASOs invariably decreased Pol II-Ser2p levels at the promoters
of the trans targets examined as well as mRNA expression of
these genes in C4-2, but not in the non-prostatic cell lines exam-
ined (Figures S3A–S3C). Chromatin isolation by RNA purification
(ChIRP) assays showed that PSA eRNA was present in the pro-
moters of these genes (Figure S3D). The effects of PSA eRNA
on total, unphosphorylated, and Ser5-phosphorylated Pol II,
CYCLIN T1, and AR binding at the promoters of these trans
target loci were validated by ChIP-qPCR (Figure S3E). PSA
eRNA knockdown mitigated enhancer-promoter looping in cis
(PSA) but not in trans loci (TMPRSS2 and NKX3.1) (Figure S3F).
These data indicate that PSA eRNA regulates Pol II-Ser2p levels
at a number of trans target loci.
PSA eRNA Binds to CYCLIN T1 of the P-TEFb Complex
In agreement with the high expression of PSA eRNA in C4-2 cells
(Figure 1E) and the role of PSA eRNA in the regulation of Pol II-
Ser2p (Figures 3B–3D), CDK9-mediated Pol II-Ser2p was
much higher in C4-2 than that in LNCaP cells (Figure S4A). Be-
sides P-TEFb, other factors such as CDK12 and the phospha-
tase FCP1 are also involved in the regulation of Pol II-Ser2p
(Cho et al., 2001; Davidson et al., 2014; Zhou et al., 2012). While
dissociation of NELF from the paused Pol II cannot affect Pol II-
Ser2p, it plays an essential role in promoting transcription elon-
gation (Yamaguchi et al., 1999). Given that eRNA induces
transcription elongation by binding to and causing the release
of the E subunit of NELF (NELF-E) from the paused Pol II (Schau-
kowitch et al., 2014), we examined whether PSA eRNA binds to
these factors. A biotin-labeled RNA pulldown assay demon-
strated that only CDK9 and CYCLIN T1 were associated with
PSA eRNA, and these results were confirmed by reciprocal604 Cell Reports 15, 599–610, April 19, 2016RNA immunoprecipitation (RIP) assays (Figures 4A and 4B).
In vitro kinase assays demonstrated that PSA eRNA enhanced
P-TEFb complex-mediated phosphorylation of Pol II CTD (Fig-
ure 4C). Accordingly, concomitant PSA eRNA and CDK9
knockdown failed to further decrease expression of the cis and
trans targets of PSA eRNA, compared with CDK9 knockdown
alone (Figure S4B), suggesting that the function of PSA eRNA
is mainly mediated through P-TEFb. Consistent with the GRO-
seq results (Wang et al., 2011), our RNA-seq data showed that
high-level eRNA signals were mainly detected in a 350-nt
peak region (Figures 1E and S4C). In vitro RNA binding assays
demonstrated that GST (glutathione S-transferase)-CYCLIN
T1, but not GST-CDK9 or GST alone, preferentially bound to
RNAs that were in vitro transcribed from the eRNA peak region,
in comparison to those synthesized from a control region (Fig-
ures S4C and S4D). A similar specific interaction between the
PSA eRNA peak region and endogenous CYCLIN T1 was de-
tected in C4-2 cells using sonication RIP assay (Figure 4D).
ChIRP and ChIP assays demonstrated that PSA eRNA and
CYCLIN T1 bound to the same region of the PSA promoter
(Figure 4E).
Like other CDKs, threonine 186 phosphorylation (T186p) in
the T-loop is required for CDK9 activation (Li et al., 2005),
and CDK7 is responsible for this phosphorylation (Larochelle
et al., 2012). While CDK7 knockdown decreased T186p in
both LNCaP and C4-2 cells (Figure S4E), little or no difference
in the levels of CDK9 T186p was detected in these two cell lines
(Figure S4F). Knockdown of PSA eRNA had no effect on T186p
in C4-2 cells (Figure S4G). Notably, previous findings show
that, while T186p is essential for CDK9 activation, T186-phos-
phorylated CDK9 can be functionally inactive, due to its binding
by 7SK and HEXIM1/2, the inhibitory subunit of P-TEFb
(Zhou et al., 2012). Thus, PSA eRNA may regulate Pol II
Ser2p and the P-TEFb activity through mechanisms dependent
on CYCLIN T1 binding but independent of CDK9 T-loop
phosphorylation.
Identification of a TAR-L Motif in PSA eRNA that
Promotes P-TEFb Activation
We demonstrated that deletion of a 50-bp region (3,904 to
3,854 relative to TSS) within the PSA eRNA peak region largely
diminished PSA eRNA binding to the recombinant CYCLIN T1
protein in vitro and the CYCLIN T1-CDK9 protein complex in
cells (Figure 5A; Figure S5A). Deletion of the same region also
significantly abolished the transcriptional activity of the PSA re-
porter gene (Figure 5B). It is worth noting that, while deletion of
the 3,904/3,854 region abrogated PSA eRNA binding with
the CYCLIN T1/CDK9 complex in vitro, it did not completely
abolish PSA reporter gene activity in cells (Figures 5A and 5B).
A plausible reason is that the intact endogenous PSA eRNA
may act in trans to activate the reporter gene in the presence
of endogenous CYCLIN T1/CDK9 complex. This concept was
further supported by the finding that the transcriptional activity
of a promoter-alone reporter gene, which lacks any potential
cis elements from the enhancer region, was also diminished by
PSA eRNA knockdown (Figure S5B).
Within the CYCLIN T1-binding region (3,904 to approxi-
mately 3,854) of PSA eRNA, we identified a TAR RNA-like
Figure 4. PSA eRNA Binds to P-TEFb
(A) C4-2 cell lysate was incubated with in-vitro-
transcribed, biotin-labeled RNAs followed by
western blots. Input RNA was analyzed by dot-
blot hybridization. Asterisk indicates non-specific
band.
(B) C4-2 cell lysate was incubated with IgG,
CDK12, FCP1, NELF-E, or CYCLIN T1 antibodies
for RIP, and RIP RNAs were analyzed by RT-qPCR.
Data indicate means ± SD (n = 3). *p < 0.05.
(C) Left: silver staining of SFB-CDK9 immunopre-
cipitated from 293T cells and western blot (WB).
Pound signs indicate nonspecific bands. Middle:
Coomassie blue staining of GST-Pol II-CTD (as-
terisks) used for kinase assay. Right: in vitro CDK9
kinase assay followed by western blot. IP, immu-
noprecipitate.
(D) Top: schematic diagram of the PSA eRNA peak
region and primers for RIP assay. Bottom: soni-
cated C4-2 cell lysate was subjected to RIP
with IgG or CYCLIN T1 antibodies and RT-qPCR.
*p < 0.05.
(E) ChIP assay using IgG or CYCLIN T1 antibodies
or ChIRP assay using biotin-labeled LacZ or PSA
eRNA-specific DNA probes and streptavidin beads
in C4-2 cells. Neg Ctrl, negative control.
For (D) and (E), real-time PCR data indicate
means ± SD (n = 3). *p < 0.05.(TAR-L) motif that shares a similar secondary structure with TAR
RNA and the 30 end of 7SK snRNA (Figures 5C, S5C, and S5D).
Deletion of the TAR-L motif largely diminished PSA eRNA bind-
ing with CYCLIN T1 in vitro (Figure 5D), suggesting that TAR-L
is important for CYCLIN T1 binding. We further showed that
the in vitro and in vivo interactions of these molecules were
both largely diminished by the addition or expression of 7SK,
respectively (Figures 5E and S4D). No association of PSA
eRNAwith HEXIM1was detected by RIP assay in C4-2 cells (Fig-
ure 5E). ChIP assays demonstrated that knockdown of PSA
eRNA by ASOs increased HEXIM1 binding in the promoters of
both cis and trans targets of PSA eRNA (Figures S5E and S5F).
These data suggest that PSA eRNA promotes P-TEFb activation
by functioning as a competitor of 7SK.
To further characterize the function of the TAR-L motif,
we generated a unique PSA reporter gene construct,
PSA-50Insert-Luc, by inserting a 15-bp non-specific sequence
in the region 50 to the enhancer androgen-responsive elementC(ARE). This insertion did not affect the
transcriptional activity of the reporter but
makes the reporter construct suitable for
ChIP assessment of AR binding (Fig-
ure S5G). Deletion of TAR-L impaired the
transcriptional activity of this reporter
gene, and the effect was reversed by re-
placing TAR-L with TAR RNA (nt 20–42)
or the 30 end (nt 302–324) of 7SK (Fig-
ure 5F). However, reversing the orienta-
tion of the TAR-L motif inhibited the
reporter gene activity (Figure 5F). Simi-
larly, replacement of TAR-L with TAR orthe 30 end of 7SK in a reversed orientation failed to restore the re-
porter gene activity (Figure 5G), which is consistent with the
previous report that the orientation of 7SK and TAR is function-
ally important (Dingwall et al., 1990). These data argue that the
effect of TAR-L deletion was unlikely caused by loss of any po-
tential cis-regulatory element within this region. These genetic
manipulations did not affect AR binding to the PSA enhancer
and promoter of the reporter gene (Figure S5H). Disruption of
the hairpin structure by introducingmutations in the complemen-
tary base pairs in the TAR-L motif impaired PSA promoter tran-
scriptional activity in both C4-2 and LNCaP cells (Figure S5I).
Putative TAR-L sequenceswere also identified in other highly ex-
pressed AR-eRNAs (Figure S5J). Similar to the PSA eRNA, the
TAR-L motif in TMPRSS2 and SLC16A7 eRNAs was important
for CYCLIN T1 binding in vitro (Figure S5K). They also bound
to CYCLIN T1 in cultured cells, and their binding was largely
diminished by 7SK expression (Figure S5L). Thus, we have iden-
tified a TAR-L module in AR-eRNAs that is critical for eRNAell Reports 15, 599–610, April 19, 2016 605
Figure 5. Identification of a TAR-L Motif in PSA eRNA Important for P-TEFb Binding and Gene Transactivation
(A) Left: the broken lines represent the deletion regions in PSA eRNA. Right: in-vitro-transcribed wild-type andmutated PSA eRNAswere incubatedwith C4-2 cell
lysates. eRNA-bound proteins and RNA inputs were subject to SDS-PAGE and dot-blot hybridization, respectively. Neg. ctrl, negative control.
(B) Measurement of the luciferase activity of PSA-Luc reporter constructs (containing an eRNA region that was either wild-type or mutated) in C4-2 cells. Data
indicate means ± SD (n = 3). *p < 0.05.
(C) Structural comparison of the HIV-1 TAR RNA, the 30 end of 7SK snRNA and the TAR-L motif in PSA eRNA.
(D) Examination of CYCLIN T1 binding to wild-type andmutated PSA eRNA. PSA eRNA pulled down by GST or GST-CYCLIN T1 was detected by RT-qPCR. Data
indicate means ± SD (n = 3). *p < 0.05.
(E) C4-2 cells were transfected with pcDNA3.1 or pcDNA3.1-7SK plasmids or lysate of untransfected cells was added with in vitro transcribed 7SK prior to RIP
assay. Data indicate means ± SD (n = 3). *p < 0.05.
(F and G) Left: schematic diagram of the PSA-50 Insert-Luc report construct containing an eRNA region. The fragment in orange represents the PSA eRNA peak
region. Right: luciferase measurement in C4-2 cells. Data indicate means ± SD (n = 3). *p < 0.05; **p < 0.01. Del, deletion; Rev, reverse.binding to CYCLIN T1, P-TEFb activation, and eRNA-mediated
AR target gene transcription.
Importance of the Endogenous TAR-L Element in
P-TEFb Activation in Cells
To further our understanding of the function of the TAR-L motif
in PSA eRNA, we used TALEN-based DNA editing (Bedell et al.,
2012) to specifically delete the TAR-L motif or an adjacent re-
gion (negative control) in the genome of C4-2 cells (Figure S6A).
Similar to LNCaP, C4-2 cells are tetraploid (4n) with four copies
of chromosome 19 where the PSA gene is located (Murillo
et al., 2006). We acquired three independent TAR-L partial606 Cell Reports 15, 599–610, April 19, 2016(50%) deletion subclones in which this motif was completely
removed and replaced by non-specific sequences (Figures
S6B–S6D and S6G). We also obtained two control subclones
where the target sequence was partially (50% or 75%)
deleted, and both deletions had no significant effect on PSA
eRNA and mRNA expression in C4-2 cells (Figures S6E–S6H).
While TAR-L deletion had little or no effect on PSA eRNA
expression (Figure 6A), it significantly downregulated PSA
mRNA expression, decreased Pol II-Ser2p levels at the PSA lo-
cus, and increased total Pol II and HEXIM1 binding to the PSA
promoter, but it did not affect AR and CYCLIN T1 binding, un-
phosphorylated Pol II levels, and enhancer/promoter looping
Figure 6. The TAR-L Motif in the Endogenous PSA eRNA Is Important for Its Target Gene Expression, Pol II-Ser2p Levels, and CRPC Cell
Growth
(A) Left: schematic diagram showing C4-2 cell clones expressing PSA eRNA in which the TAR-L motif or a control (Ctrl) region was deleted by TALENs. WT, wild-
type. Right: expression of PSA eRNA and mRNA in C4-2 TAR-L deletion stable cells measured by RT-qPCR. Data indicate means ± SD (n = 3). ***p < 0.001,
compared to control D1. NS, not significant.
(B) ChIP-qPCR analysis of Pol II Ser2p at the PSA gene locus in C4-2 TALEN-modified cells. Data indicate means ± SD (n = 3). *p < 0.05, compared to controlD1.
(C) ChIP-qPCR analysis of HEXIM1 binding at the PSA promoter. ChIP DNA was analyzed by real-time PCR. Data indicate means ± SD (n = 3). **p < 0.01,
compared to control D1.
(D) ChIP-qPCR analysis of Pol II-Ser2p at the trans target loci VEGFA and SLC45A3 in C4-2 TALEN-modified cells. Data indicate means ± SD (n = 3). *p < 0.01,
compared to control D1.
(E and F) Viability of mock or ASO-transfected, or control or TALEN-modified, C4-2 cells was measured by MTS assay. Data indicate means ± SD (n = 6).
**p < 0.01; ***p < 0.001, compared to control 1.
(G) A hypothetic model of PSA eRNA-mediated cis- and trans-activation of the P-TEFb complex and gene transcription.(Figures 6A–6C and S6I–S6L). Similar results were obtained for
the PSA eRNA trans targets examined (Figures 6D, S6L, and
S7A–S7F). Moreover, PSA eRNA expression was correlatedwith mRNA expression of these trans target genes in CRPC pa-
tient samples (Figure S7G). We conclude that the TAR-L motif
is required for PSA eRNA-mediated regulation of Pol II-Ser2pCell Reports 15, 599–610, April 19, 2016 607
levels at both cis and trans target loci and their mRNA expres-
sion in CRPC cells.
We demonstrated that knockdown of PSA eRNA (not PSA
mRNA) by ASOs or siRNA not only specifically decreased the
viability of C4-2 CRPC cells but also enhanced the inhibitory ef-
fect of the antiandrogen bicalutamide rather than enzalutamide
(Figures 6E, S7H, and S7I). Deletion of the TAR-Lmotif by TALEN
also significantly diminished the viability of C4-2 cells (Figure 6F),
and this result was consistent with the finding that TAR-L dele-
tion significantly decreased expression of the trans targets that
are important for cell-cycle progression, proliferation, and sur-
vival (Figure S7A).
DISCUSSION
Activation of the P-TEFb complex is important for Pol II-Ser2p,
release of paused Pol II, and gene transcription, but the underly-
ing mechanisms are not fully understood. An essential step in
P-TEFb activation is its dissociation from the inhibitory subunit
composed of 7SK snRNA and HEXIM1/2 (Liu et al., 2013;
Nguyen et al., 2001; Yang et al., 2001). HIV-1 Tat (via interaction
with TAR RNA) and BRD4 (via interaction with JMJD6) are
capable of extracting P-TEFb out from the inhibitory 7SK/
HEXIM1/2 complex by competing away and mediating the de-
capping/demethylation of 7SK, respectively (Egloff et al., 2006;
Liu et al., 2013; Roy et al., 1990).We identified a TAR-L sequence
inPSA eRNA and other AR-eRNAs that share a similar secondary
structure with the 30 end of 7SK snRNA and HIV-1 TAR RNA. We
provided evidence that PSA eRNA binds to CYCLIN T1, but not
HEXIM1, and that the binding is mediated by the TAR-L motif.
Accordingly, we showed that PSA eRNA promotes P-TEFb acti-
vation as a competitor of 7SK. Through reporter gene and
TALEN-based gene editing assays, we provided in vitro and
in vivo evidence that the TAR-L motif in PSA eRNA is important
for P-TEFb activation and Pol II-Ser2p. Thus, our findings reveal
a previously undefined mechanism of P-TEFb activation and a
function of eRNA in regulating P-TEFb activation, Pol II-Ser2p,
and gene transcription in cis and in trans (Figure 6G). It is worth
noting that HIV-1 Tat forms a complex with TAR RNA to activate
P-TEFb by competing away the inhibitory subunit 7SK and
HEXIM1/2 (Zhou et al., 2012). At present, however, whether
PSA eRNA also requires a similar partner activator to activate
the P-TEFb complex is unclear, and further investigation is
warranted.
Reactivation of AR is a central mechanism for CRPC progres-
sion. Targeting the androgen-AR axis by the second-generation
endocrine therapies (e.g., abiraterone and enzalutamide) has
been effective for CRPC treatment in clinic. However, drug resis-
tance ultimately develops in some patients, presumably due to
the expression of AR splice variants and/or other undefined
mechanisms (Antonarakis et al., 2014). Enhancer functions are
important for tissue-specific gene expression and cell-lineage
development (Maston et al., 2006; Ørom and Shiekhattar,
2013; Xie and Ren, 2013). A recent seminal finding is that en-
hancers make eRNAs. In the present study, eRNA profiling anal-
ysis has allowed us to define a signature set of AR-regulated
genes whose expression associates with CRPC progression in
patients. These findings imply that aberrant eRNA expression608 Cell Reports 15, 599–610, April 19, 2016represents a new gauge of abnormal AR activity in CRPC. We
further revealed that, through both the cis and transmechanisms
of action, PSA eRNA plays a key role in increasing aberrant AR
activity and CRPC cell viability. These results highlight a possibil-
ity that effective targeting of PSA eRNA, alone or in combination
with other anticancer agents such as the antiandrogens bicaluta-
mide or enzalutamide, could serve as a therapeutic option for
CRPC treatment in clinic. It is worth noting that, in the present
study, we mainly focused on the investigation of the functional
importance of PSA eRNA. With the unfolding of the function of
other AR-eRNAs, it is conceivable that combined knockdown
of a set of AR-eRNAs may result in greater inhibition or elimina-
tion of CRPC growth. We envision that, although the mecha-
nisms underlying aberrant AR activity in CRPC have not been
fully understood, blockage of the activities of key enhancers by
targeting functional AR-eRNAs may open up a new avenue for
CRPC therapy.
Despite being extensively utilized as a biomarker for prostate
cancer diagnosis and prognosis, as well as a model gene to
study androgen action, the significance of the PSA gene in pros-
tate cancer growth and survival has not been well established.
We demonstrated that knockdown of PSA eRNA by ASOs
largely decreased the viability of C4-2 CRPC cells, implying the
significance of PSA eRNA in CRPC cell growth and survival.
Deletion of the TAR-L motif by TALEN also significantly dimin-
ished the viability of C4-2 cells, and this result was consistent
with the finding that TAR-L deletion significantly decreased
expression of the trans targets of PSA eRNA that are important
for cell-cycle progression, proliferation, and survival. Thus, in
addition to the cis function in the regulation of PSA mRNA
expression, we found that PSA eRNA can trans-regulate expres-
sion of a subset of genes involved in androgen action; cell-cycle
progression; and cell proliferation, survival, and growth, as well
as migration and invasion. Our data reveal that, as one of the
genes most strongly transactivated by AR signaling, the PSA
gene produces eRNAs from its enhancer to ‘‘magnify’’ AR action
by trans-regulating a large number of downstream target genes.
Our findings also suggest that, besides being as a biomarker, the
PSA gene can produce eRNAs from its enhancer that are func-
tionally important. Thus, PSA represents an unconventional
class of genes whose tumor biological significance is not solely
reflected by their protein function but also by other functional
components such as eRNA.
In summary, we identified a TAR-L motif in AR-eRNAs and
demonstrated that this motif in PSA eRNA is important for
CYCLIN T1 binding, P-TEFb activation, Pol II-Ser2p, cis- and
trans-regulation of transcription of target genes, and CRPC cell
growth (Figure 6G). Therefore, our findings not only reveal a pre-
viously undefined mechanism of action for enhancer RNAs in
both cis- and trans-regulation of gene transcription but also
uncover a new mode of P-TEFb activation. These results sug-
gest that targeting AR-eRNAs using new methods such as
ASOs represent an alternative arsenal of AR-directed therapies
for CRPC.EXPERIMENTAL PROCEDURES
For further details, see the Supplemental Experimental Procedures.
Cell Lines, Cell Culture, and Reagents
LNCaP, MCF-7, and HepG2 cell lines were purchased from ATCC. The C4-2
cell line was purchased from UroCorporation. Mibolerone and bicalutamide
were purchased from Sigma-Aldrich. Enzalutamide was kindly provided by
Medivation.
ChIP-Seq, Data Analysis, and ChIP-qPCR
ChIP and ChIP-seq library preparation were performed as described previ-
ously (Boyer et al., 2005), and high-throughput sequencing was performed us-
ing HiSeq2000 platforms at theMayoGenomeCore. The detail procedures are
shown in the Supplemental Information.
Design andScreening of Highly OptimizedGeneration-2.5 Antisense
Oligonucleotides
All antisense oligonucleotides (ASOs) contained a full phosphorothioate
backbone. A large number of ASOs targeting sense-strand PSA (or KLK3)
eRNA were screened by Ionis Pharmaceuticals for highly efficient reduction
of PSA eRNA. The detail procedures are shown in the Supplemental
Information.
Transcription Activator-like Effector Nuclease Construction
Transcription activator-like effector nucleases (TALENs) were designed using
Mojo Hand software. The detail procedures are shown in the Supplemental
Information.
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